Pharmacologic Approach to Therapy of Brugada Syndrome: Quinidine as an Alternative to ICD Therapy?

The Brugada Syndrome: From Bench to Bedside

Volumn , Issue , 2007, Pages 202-211

  Belhassen, Bernard ^a,b   Viskin, Sami ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Antiarrhythmic medications; Implantable cardioverter defibrillator (ICD); Quinidine therapy; Treatment of Brugada syndrome; Ventricular fibrillation (VF)

Indexed keywords

EID: 33750049372     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470994900.ch18     Document Type: Chapter

References (38)

1. Brugada P, Brugada J. Right bundle branch block, persistent ST-segment elevation and sudden cardiac death. J. Am. Coll. Cardiol. 1992; 20:1391-1396.
2. Antzelevitch C, Brugada P, Brugada J et al. Brugada syndrome: 1992-2002. A historical perspective. J. Am. Coll. Cardiol. 2003;41:1665-1671.
3. Chen Q, Kirsh GE, Zhang D et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998; 392:293-296.
4. Weiss R, Barmada M, Nguyen T et al. Clinical and molecular heterogeneity in the Brugada syndrome. A novel gene locus on chromosome 3. Circulation 2002;105:707-713.
5. Priori SG, Napolitano C, Gasparini M et al. The Brugada syndrome: clinical and genetic heterogeneity of right bundle branch block and ST-elevation syndrome. A prospective evaluation of 52 families. Circulation 2000; 102; 2509-2515.
6. Priori SG, Aliot E, Blomstrom-Lundqvist C et al. Task Force on sudden cardiac death of the European Society of Cardiology. Eur. Heart J. 2001; 22:1374-1450.
7. Alings M, Wilde A. 'Brugada syndrome. Clinical data and suggested pathophysiological mechanism. Circulation 1999;99:666-673.
8. Nademanee K, Veerakul G, Mower M et al. Defibrillator versus beta-blockers for unexplained death in Thailand (DEBUT): a randomized clinical trial. Circulation 2003; 107:2221-2226.
9. Belhassen B, Pelleg A, Miller HI et al. Serial electrophysio-logical studies in a young patient with recurrent ventricular fibrillation. Pacing Clin. Electrophysiol. 1981;4:9299.
10. Belhassen B, Shapira I, Shoshani D et al. Idiopathic ventricular fibrillation: inducibility and beneficial effects of class I antiarrhythmic agents. Circulation 1987;75:809-816.
11. Belhassen B,Viskin S, Fish R et al. Effects ofelectrophysio-logic-guided therapy with class 1A antiarrhythmic drugs on the long-term outcome of patients with idiopathic ventricular fibrillation with or without the Brugada syndrome. J. Cardiovasc. Electrophysiol. 1999; 10:1301-1312.
12. Antzelevitch C. The Brugada syndrome. J. Cardiovasc. Electrophysiol. 1998; 9:513-516.
13. Gussak I, Antzelevitch C, Bjerregaard P et al. The Brugada syndrome: clinical, electrophysiological and genetic aspects. J.Am. Coll. Cardiol. 1999; 33:5-15.
14. Antzelevitch C. The Brugada syndrome: ionic basis and arrhythmia mechanisms. J. Cardiovasc. Electrophysiol. 2001; 12:268-272.
15. Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation 1999;100:1660-1666.
16. Nakajima T, Kurachi Y, Ito H et al. Anticholinergic effects of quinidine, disopyramide, and procainamide in isolated atrial myocytes: mediation by different molecular mechanisms. Circ. Res. 1989; 64:297-303.
17. Belhassen B, Shapira I, Sheps D et al. Programmed ventricular stimulation using up to two extrastimuli and repetition of double extrastimulation for induction of ventricular tachycardia: a new highly sensitive and specific protocol.Am.J. Cardiol. 1990;65:615-622.
18. Viskin S, Belhassen B. Clinical problem-solving. When you only live twice. N. Engl J.Med. 1995;332:1221-1225.
19. Suzuki H, Torigoe K, Numata O et al. Infant case with a malignant form of Brugada syndrome. J. Cardiovasc. Electrophysiol. 2000; 11:1277-1280.
20. Garg A, Finneran W, Feld G. Familial sudden cardiac death associated with a terminal QRS abnormality on surface 12-lead electrocardiogram in the index case. J. Cardiovasc. Electrophysiol. 1998; 9:642-647.
21. Chinushi M, Aizawa Y, Ogawa Y et al. Discrepant drug action of disopyramide on ECG abnormalities and induction of ventricular arrhythmias in a patient with Brugada syndrome. J. Electrocardiol. 1997; 30:133-136.
22. Alings M, Dekker L, Sadee A et al. Quinidine induced electrocardiographic normalization in two patients with Brugada syndrome. Pacing Clin. Electrophysiol. 2001;24:1420-1422.
23. Belhassen B, Viskin S, Antzelevitch C. The Brugada syndrome: is an implantable cardioverter defibrillator the only therapeutic option. Pacing Clin. Electrophysiol. 2002;25:1634-1640.
24. Miyazaki T, Mitamura H, Miyoshi S et al. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J. Am. Coll. Cardiol. 1996; 27:1061-1070.
25. Brugada P, Brugada R, Mont L et al. Natural history of Brugada syndrome: the prognostic value of programmed electrical stimulation of the heart. J. Cardiovasc. Electrophysiol. 2003; 14:455-457.
26. Bezzina C, Veldkamp MW, van Den Berg MP et al. A single Na(+) channel mutation causing both long-QT and Brugada syndromes. Circ.Res. 1999;85:1206-1213.
27. Chalvidan T, Deharo JC, Dieuzaide P et al. Near fatal electrical storm in a patient equipped with an implantable car-dioverter-defibrillator for Brugada syndrome. Pacing Clin. Electrophysiol. 2000; 23:410-412.
28. Nakamura M, Isobe M, Imamura H. Incessant ventricular fibrillation attacks in a patient with Brugada syndrome. Int. J. Cardiol. 1998;64:205-206.
29. Tanaka H, Kinoshita O, Uchikawa S et al. Successful prevention of recurrent ventricular fibrillation by intravenous isoproterenol in a patient with Brugada syndrome. Pacing Clin. Electrophysiol. 2001; 24:1293-1294.
30. Hegel MT, Griegel LE, Black C et al. Anxiety and depression in patients receiving implanted cardioverter-defibrillators: a longitudinal investigation. Int. J. Psychiatry 1997; 27:57-69.
31. Pinski SL, Fahy GJ. The proarrhythmic potential of implantable cardioverter-defibrillators. Circulation 1995;92:1651-1664.
32. Joglar JA, Kessler DJ, Welch PJ, et al. Effects of repeated electrical defibrillations on cardiac troponin I levels. Am. J. Cardiol. 1999; 83:270-272.
33. Pires LA, Hull ML, Nino CL et al. Sudden death in recipients oftransvenous implantable cardioverter defibrillator systems. Terminal events, predictors, and potential mechanisms. J. Cardiovasc. Electrophysiol. 1999;10:1049-1056.
34. Bigersdotter-Green U, Rosenquist M, Lindemans FW et al. Holter documented sudden death in a patient with an implanted defibrillator. Pacing Clin. Electrophysiol. 1992;15:1008-1014.
35. Glikson M, Friedman PA. The implantable cardioverter defibrillator. Lancet2001;357:1107-1117.
36. Schwartzman D, Nallamothu N, Callans DJ et al. Postoperative lead-related complications in patients with nonthoracotomy defibrillation lead systems. J. Am. Coll. Cardiol. 1995;26:776-786.
37. Priori SG, Napolitano C, Giordano U et al. Brugada syndrome and sudden cardiac death in children. Lancet2000;355:808-809.
38. Stix G, Bella PD, Carbucicchio C et al. Spatial and temporal heterogeneity of depolarization and repolarization may complicate implantable cardioverter defibrillator therapy in Brugada syndrome. J. Cardiovasc. Electrophysiol. 2000; 11:516-521.